1.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
2.	Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
3.	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848
4.	Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: AML08, 5R01CA138744, 1R01CA115422, NCT00703820
5.	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: NCI, Other Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
6.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000706370, COG-AALL1131, AALL1131, NCT01406756
7.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
8.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
9.	Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1066306 (0408), NCT00156013
10.	Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL Phase: Phase II, Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: L 9471, NCT00529360
11.	Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: EORTC-06061, EU-20905, 2006-004912-28, GIMEMA-AML-14A, EudraCT-2006-004912-28, NCT00838240
12.	Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Responded to Treatment Phase: Phase II, Phase I Type: Treatment Status: Active Age: 60 and over Sponsor: NCI, Other Protocol IDs: 2302.00, NCI-2010-00039, P30CA015704, FHCRC-2302.00, IR-6853, NCT00839982
13.	Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: 2009-0536, NCT01160354
14.	A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: SPON 845-10, 2010-021444-18, 10/MRE09/27, NCT01236144
15.	Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0788, NCT01289457
16.	Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RHM CAN0638, 2008-007043-14, NCT01422603
17.	Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: KS-2009-003, 2010-021719-18, NCT01534702
18.	Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2012-0249, NCT01629511
19.	Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 65 Sponsor: Other Protocol IDs: 2012-0506, NCT01701986
20.	Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 64 Sponsor: Other Protocol IDs: 2012-1064, NCT01794702
21.	Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929
22.	Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Phase: Phase II Type: Treatment Status: Active Age: Under 60 Sponsor: Other Protocol IDs: 2008-0363, NCT00857389
23.	Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: BRD 08/7-J, NCT00863148
24.	Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0092, NCT00903760
25.	The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) Phase: Phase II Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 2006.456/50, NCT00932412